Author: Bella Hayes
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC Source link
CRBU DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action – CRBU Source link
NOG Provides Fourth Quarter 2024 Operational Update; Provides Initial 2025 Capital and Production Guidance; Announces Signing of $40 Million Bolt-On Acquisition in First Quarter Source link
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference – Hawaii ® Source link
FRANKSPEECH NETWORK, INC further known as Mike Lindell Media Corp. (OTC Pink FSBN) Announces America's Mayor, Rudolph "Rudy" Giuliani Added to the Company Board of Directors. Source link
Federman & Sherwood Announces Filing the first Securities Class Action Lawsuit Against Mullen Automotive, Inc. (NASDAQ: MULN), Jonathan New, and David Michery Source link
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages ModivCare Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MODV Source link
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Edison International Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – EIX Source link
New to the Street Announces 12-Month Partnership With ROADZEN – Monthly Fox Business & Bloomberg Coverage, Earned Media, TV Commercials, and Times Square Billboards Source link
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410”a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Source link
